Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The unique properties of the tumour microenvironment can be exploited by using recombinant anaerobic clostridial spores as highly selective gene delivery vectors. Although several recombinant Clostridium species have been generated during the past decade, their efficacy has been limited. Our goal was to substantially improve the prospects of clostridia as a gene delivery vector. Therefore, we have assessed a series of nitroreductase (NTR) enzymes for their capacity to convert the innocuous CB1954 prodrug to its toxic derivative. Among the enzymes tested, one showed superior prodrug turnover characteristics. In addition, we established an efficient gene transfer procedure, based on conjugation, which allows for the first time genetic engineering of Clostridium strains with superior tumour colonisation properties with high success rates. This conjugation procedure was subsequently used to create a recombinant C. sporogenes overexpressing the isolated NTR enzyme. Finally, analogous to a clinical setting situation, we have tested the effect of multiple consecutive treatment cycles, with antibiotic bacterial clearance between cycles. Importantly, this regimen demonstrated that intravenously administered spores of NTR-recombinant C. sporogenes produced significant antitumour efficacy when combined with prodrug administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Purdy, D., O'Keeffe, T. A. T., Elmore, M., Herbert, M., McLeod, A., Bokori‐Brown, M., Ostrowski, A., & Minton, N. P. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03134.x · Cited by 255 · cited 4×
“…M-55 C. novyi-NT pMTL555 (pIM13) 1.44 10 7 1.84 10 7 ND pMTL9501/pCTC41 (pAMb1) 1.18 10 6 1.27 10 6 1.80 10 7 pMTL9401 (pCB102) 8.86 10 5 ND ND pMTL9611 (pIP404) 8.3 10 6 ND ND pMTL9301 (pCD6) 4.00 10 5 ND ND Plasmids pMTL9301, pMTL9401, pMTL9501 and pMTL9611 are described by Purdy et al (2002).”
MethodSelf-citationExpression of cloned homologous fermentative genes in Clostridium acetobutylicum ATCC 824
Mermelstein, L. D., Welker, N. E., Bennett, G. N., & Papoutsakis, E. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-190 · Cited by 249
Cited by
A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites
Dodd, D., Spitzer, M. H., Van Treuren, W., Merrill, B. D., Hryckowian, A. J., Higginbottom, S. K., Le, A., Cowan, T. M., Nolan, G. P., Fischbach, M. A., et al. (2017) · Nature · doi:10.1038/nature24661 · Cited by 1,425
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Reduction of polynitroaromatic compounds: the bacterial nitroreductases
Roldán, M. D., Pérez-Reinado, E., Castillo, F., & Moreno-Vivián, C. (2008) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2008.00107.x · Cited by 458
Bioengineered and biohybrid bacteria-based systems for drug delivery
Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B.-W., Singh, A. V., & Sitti, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.007 · Cited by 368
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“Thus, genes expressing enzymes that convert the innocuous prodrug to toxic derivative can be introduced into clostridium, and injection of the transgenic bacterial spores can decrease systematic side effects when combined with nontoxic prodrug administration.(408)”
BackgroundTherapeutic bacteria to combat cancer; current advances, challenges, and opportunities
Sedighi, M., Zahedi Bialvaei, A., Hamblin, M. R., Ohadi, E., Asadi, A., Halajzadeh, M., Lohrasbi, V., Mohammadzadeh, N., Amiriani, T., Krutova, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2148 · Cited by 308
Integration of DNA into bacterial chromosomes from plasmids without a counter-selection marker
Heap, J. T., Ehsaan, M., Cooksley, C. M., Ng, Y.-K., Cartman, S. T., Winzer, K., & Minton, N. P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1321 · Cited by 201
Self-citationGanai, S., Arenas, R. B., & Forbes, N. S. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605403 · Cited by 179
“…agents (Wei et al, 2008) and have been shown to selectively target tumours after intravenous injection: Salmonella (Low et al, 1999), Escherichia (Yu et al, 2004; Stritzker et al, 2007), Clostridium (Lemmon et al, 1997; Dang et al, 2001; Theys et al, 2006), and Bifidobacterium (Yazawa et al, 2001).”
BackgroundBacteria as vectors for gene therapy of cancer
Baban, C. K., Cronin, M., O’Hanlon, D., O’Sullivan, G. C., & Tangney, M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.6.13146 · Cited by 175
Ng, Y. K., Ehsaan, M., Philip, S., Collery, M. M., Janoir, C., Collignon, A., Cartman, S. T., & Minton, N. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056051 · Cited by 175
“sporogenes [38].”
Self-citationNanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy
Hu, Y., Liu, C., & Muyldermans, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01442 · Cited by 171
“The efficacy of Clostridiumdirected tumor therapy (CDAT) has been demonstrated in experimental models as a vehicle for tumor-specific delivery of prodrug converting enzymes (128, 129) and to enhance radiotherapy and chemotherapy (130–132).”
Background
Metadata
- Authors
- Theys, J., Pennington, O., Dubois, L., Anlezark, G., Vaughan, T., Mengesha, A., Landuyt, W., Anné, J., Burke, P. J., Dûrre, P., Wouters, B. G., Minton, N. P., & Lambin, P.
- Venue
- British Journal of Cancer
- Published
- 2006-10-03
- Volume
- 95
- Issue
- 9
- Pages
- 1212-1219
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2029243931
- Cited by
- 132
- References
- 2
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.